We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+0.59%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$266M
AUM Growth
+$34.2M
Cap. Flow
+$31.7M
Cap. Flow %
11.9%
Top 10 Hldgs %
46.64%
Holding
93
New
15
Increased
28
Reduced
14
Closed
6

Top Buys

Rank Stock Value
1
ELOX
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
+$3.95M
2
GNCA
Genocea Biosciences, Inc.
GNCA
+$2.53M
3
AUTL
Autolus Therapeutics
AUTL
+$2.24M
4
EPZM
Epizyme, Inc
EPZM
+$2.23M
5
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
+$2.16M

Top Sells

Rank Stock Value
1
VBIV
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
+$1.59M
2
ADXS
Advaxis Inc
ADXS
+$1.2M
3
ABUS icon
Arbutus Biopharma
ABUS
+$884K
4
SVRA icon
Savara
SVRA
+$813K
5
MRSN
Mersana Therapeutics
MRSN
+$603K

Sector Composition

Rank Sector Weight
1 Healthcare 91.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLGL icon
76
Sol-Gel Technologies
SLGL
$280M
$319K 0.12%
3,500
– –
ALDX icon
77
Aldeyra Therapeutics
ALDX
$95.9M
$300K 0.11%
50,000
– –
KRTX
78
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$200K 0.08%
+10,000
New +$200K
LCTX icon
79
Lineage Cell Therapeutics
LCTX
$272M
$105K 0.04%
95,000
– –
NGM
80
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$92K 0.03%
+6,265
New +$91.7K
RNTX
81
Rein Therapeutics
RNTX
$67.5M
$72K 0.03%
4,975
– –
ORMP icon
82
Oramed Pharmaceuticals
ORMP
$166M
$57K 0.02%
16,000
-10,000
-38% -$35.3K
BLCM
83
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$51K 0.02%
3,000
– –
ARCT icon
84
Arcturus Therapeutics
ARCT
$167M
$23K 0.01%
2,400
-44,855
-95% -$329K
ABUS icon
85
Arbutus Biopharma
ABUS
$863M
– –
-246,900
Closed -$884K
NERV icon
86
Minerva Neurosciences
NERV
$187M
– –
-4,511
Closed -$284K
SVRA icon
87
Savara
SVRA
$1.13B
– –
-110,275
Closed -$813K
VBIV
88
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
– –
-28,333
Closed -$1.59M
ADXS
89
DELISTED
Advaxis Inc
ADXS
– –
-202,222
Closed -$1.2M
IMMU
90
DELISTED
Immunomedics Inc
IMMU
– –
-5,052
Closed -$97K
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, DAFNA Capital Management held 93 positions worth $266M, up 15% from $232M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

DAFNA Capital Management deployed $31.7M of net new capital in Q2 2019, opening 15 new positions and adding to 28 existing holdings. Its largest new stake was Eloxx Pharmaceuticals, Inc. Common Stock: 9,375 shares worth $3.74M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 89% a quarter earlier.

On the sell side, the largest reduction was Mersana Therapeutics, an estimated $603K trimmed.

  • DAFNA Capital Management's largest Q2 2019 buy was Eloxx Pharmaceuticals, Inc. Common Stock: 9,375 shares worth $3.74M.
  • DAFNA Capital Management added most to Genocea Biosciences, Inc. in Q2 2019, an estimated $2.53M increase.
  • DAFNA Capital Management's biggest Q2 2019 reduction was Mersana Therapeutics, cutting an estimated $603K.
  • DAFNA Capital Management fully exited VBI Vaccines, Inc. New Common Stock (Canada) in Q2 2019, selling an estimated $1.59M.
  • DAFNA Capital Management's ten largest holdings make up 47% of its $266M portfolio in Q2 2019.
  • DAFNA Capital Management opened 15 new positions and closed 6 in Q2 2019.
  • DAFNA Capital Management's portfolio value rose 15% quarter-over-quarter to $266M.

Based on DAFNA Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.